Insider buying last 90 days
No open-market insider purchases were filed for EW in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every EW insider filing, plotted on the chart in Gekko.Open EW in Gekko
NYSE: EW
Edwards Lifesciences (EW) Stock Analysis & Forecast
$88.26+0.01 (0.0%)
Close on Sep 18, 2026. Page updated Sep 19, 9:19 pm ET.
Gekko Brief
AI summaryEdwards Lifesciences (EW) closes at $88.26, sitting between its 50-day average of $88.58 and 200-day average of $85.01. The GekkoIndex reads 59.7, placing the stock in the Neutral zone, down from a higher reading five days prior. Price stands 9.3% above Gekko Fair Value of $80.75, a gap that bears watching.
Recent attention has centered on Edwards' structural heart franchise, with Chief Executive Officer Bernard Zovighian outlining five growth platforms including TAVR, PASCAL, EVOQUE and SAPIEN M3, alongside a $2 billion TMTT opportunity discussed at a Deutsche Bank healthcare summit. Institutional positioning has also drawn notice: Bank of America Corp DE disclosed a new $605.40 million stake, about 6.69 million shares, making it a 1.16% owner, while Corient Private Wealth LP raised its holding by over 1,000%, adding 227,947 shares. Separately, a DCF analysis pegged intrinsic value at $53 against an $86 price, and call options volume rose 93% above average with 2,518 contracts purchased. Insider Daniel Lippis sold 619 shares at $87.51 following an option exercise, part of a pattern of sales over the past year.
Earnings arrive 29 October 2026, 39 days out and beyond a typical 20-day hold; the last report beat estimates with EPS of $0.78 versus $0.73 expected, though shares reacted -2.1%. Seasonally, the next 20 trading days have averaged -2.4% over five years, rising in only 2 of them. Analyst consensus stands at 14 buy, 3 hold, 0 sell ratings, with a $100.96 target implying 14.4% upside.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $88.26200-day averageGekko Fair Value $80.75
Key stats
- Market cap
- $50.82B
- P/E ratio
- 52.5
- Forward P/E
- 26.4
- EPS, TTM
- $1.68
- Revenue, TTM
- $6.51B
- Profit margin
- 15.4%
- Dividend yield
- —
- Beta
- 0.85
- Volume
- 4.20M avg 3.07M
- 1-year return
- +17.4%
- Typical daily move
- ±2.7%
- Typical 20-day move
- ±5%
- 50-day average
- $88.58
- 200-day average
- $85.01
- Next earnings
- Oct 29 after close
- Shares outstanding
- 576.4M
Edwards Lifesciences swing-trade checklist
Edwards Lifesciences scores 1 supportive, 2 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive2 mixed2 headwinds
- Trendmixed
Averages disagree
Close $88.26 sits between the 50-day ($88.58) and 200-day ($85.01) averages, or the averages disagree.
See the chart - GekkoIndexmixed
59.7, Neutral
Reading 59.7 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
9.3% above
Price is 9.3% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 39 days
Next report Oct 29, 2026, 39 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−2.4% on average
From this point in the calendar, the next 20 trading days averaged −2.4% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Edwards Lifesciences stock chart and price history
Edwards Lifesciences closed at $88.26 on Sep 18, 2026, +17.4% over the past year, inside a 52-week range of $72.30 to $96.29.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −4.4%
- 3 months
- +1.0%
- 6 months
- +7.0%
- 1 year
- +17.4%
The full EW chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open EW in Gekko
Follow Edwards Lifesciences through every session
Put EW on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track EW in GekkoFree for 7 days. No credit card required.
About Edwards Lifesciences
Edwards Lifesciences develops medical devices used to treat structural heart disease and to monitor patients during surgery and intensive care. Its structural heart lineup includes transcatheter valve systems for replacing or repairing damaged heart valves through minimally invasive procedures, such as the PASCAL and Cardioband devices aimed at mitral and tricuspid valve problems, along with surgical options like the INSPIRIS aortic valve, the KONECT RESILIA tissue conduit, and the HARPOON system for mitral valve repair. On the critical care side, it makes hemodynamic monitoring equipment that tracks heart function and fluid levels, including software that warns clinicians of impending drops in blood pressure.
The company reaches hospitals and other healthcare providers through its own sales staff as well as independent distributors, and it operates across the United States, Europe, Japan and other international markets.
Edwards Lifesciences was founded in 1958 and is headquartered in Irvine, California. Its shares trade on the NYSE under the ticker EW.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- edwards.com
Edwards Lifesciences GekkoIndex: the smart money zone
Edwards Lifesciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 59.7, in the Neutral zone, down 10.6 points over five sessions.
59.7Neutral
Down 10.6 points over five sessions, from the Buying zone.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 26 | +2.2% | +8.1% | ||
| Accumulation | 191 | +0.3% | +2.8% | ||
| Neutral (current zone) | 420 | +0.1% | −0.9% | ||
| Distribution | 24 | 0.0% | +3.7% | ||
| Selling | 1 | Too few readings yet | |||
Average EW share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the EW price, zone by zone.Track EW in Gekko
Is Edwards Lifesciences stock overvalued? Gekko Fair Value
Edwards Lifesciences trades 9.3% above Gekko Fair Value of $80.75, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Edwards Lifesciences shares are worth, recalculated every trading day.
$80.75
Gekko Fair Value, Sep 19, 2026
9.3% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open EW in Gekko
Edwards Lifesciences insider and Congress trading
No open-market insider purchases were filed for Edwards Lifesciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in EW were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for EW, plotted on the chart in Gekko.Open EW in Gekko
Buybacks
Edwards Lifesciences has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $53.30M
- As a share of market cap
- 0.10%
- Trailing four quarters
- $772.7M
From company filings.
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold EW.
0added0opened0trimmed2sold out
Which funds are on each side, name by name.Unlock in Gekko
Edwards Lifesciences earnings: next date and track record
Edwards Lifesciences reports on Oct 29, 2026, after the close (39 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Oct 29, 2026
Expected after the close, 39 days away
- EPS estimate
- $0.73
- Revenue estimate
- $1.68B
7 of 8reports beat the EPS estimate
±3.5%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 23, 2026 AI summary
- What they said
- Edwards Lifesciences reported a stronger-than-expected Q2 2026 with total sales of $1.74 billion, up 12.5% year-over-year, and adjusted EPS of $0.78. Management raised full-year sales guidance: total company sales to $6.6B–$6.9B (10%–11% growth), TAVR sales to $4.75B–$5.0B (8%–9%) and TMTT guidance to $760M–$780M. Full-year adjusted EPS guidance of $2.95–$3.05 was reiterated, though the company now assumes an effective tax rate at the high end of its prior 16%–19% range due to Pillar Two and California R&D credit changes. Management highlighted broad-based strength across TAVR, mitral, tricuspid and surgical therapies, with notable momentum from PASCAL, EVOQUE and early adoption of SAPIEN M3. Key upcoming catalysts include PROGRESS trial data at TCT, a draft/final CMS NCD that could enable asymptomatic coverage and streamline access, and an expected U.S. PASCAL tricuspid approval in Q4. Management presented confident tone, emphasized long-term target of ~10% company sales growth and durable growth drivers across multiple platforms.
- Guidance
- Raised full-year sales guidance: total company sales $6.6B to $6.9B (10%–11% growth). TAVR sales $4.75B to $5.0B (8%–9%). TMTT $760M to $780M (raised from $740M–$780M). Maintained full-year adjusted EPS guidance of $2.95 to $3.05 but now assumes effective tax rate at high end of 16%–19% due to Pillar Two and California R&D credit changes.
- Risks flagged
- Higher-than-expected tax burden (Pillar Two, California R&D credit restrictions), challenging second-half 2026 comps and seasonality, dependence on regulatory outcomes (CMS NCD final memo, PROGRESS trial results, PASCAL tricuspid approval), potential adoption/behavioral hurdles for new indications (asymptomatic/moderate AS), and broader macro/healthcare uncertainties noted in forward-looking statements.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 23, 2026 | $0.78 est $0.73 | $1.74B est $1.70B | −2.1% |
| Apr 23, 2026 | $0.78 est $0.73 | $1.65B est $1.60B | +3.2% |
| Feb 10, 2026 | $0.58 est $0.62 | $1.57B est $1.55B | +3.3% |
| Oct 30, 2025 | $0.67 est $0.60 | $1.55B est $1.50B | −0.3% |
| Jul 24, 2025 | $0.67 est $0.62 | $1.53B est $1.49B | +4.0% |
| Apr 23, 2025 | $0.64 est $0.60 | $1.41B est $1.40B | +6.4% |
| Feb 11, 2025 | $0.59 est $0.55 | $1.39B est $1.36B | +6.6% |
| Oct 24, 2024 | $0.67 est $0.64 | $1.35B est $1.54B | −1.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Edwards Lifesciences stock forecast and analyst price targets
Analysts’ average 12-month price target for Edwards Lifesciences is $100.96, +14.4% from the last close, from 17 firms rating the stock in the last 90 days.
$100.96consensus 12-month target, +14.4% from the last close
Now $88.26Avg $100.96
Low $85High $110
Each firm’s latest rating in the last 90 days: 17 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 11 | Jefferies | $105 | +19.0% |
| Sep 10 | Citi | $110 | +24.6% |
| Sep 10 | William Blair | — | — |
| Sep 10 | BTIG | $110 | +24.6% |
| Sep 2 | William Blair | — | — |
−0.9%average 20-day move after past Neutral readings
−2.4%average move over the next 20 trading days in the last 5 years
±2.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Edwards Lifesciences seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Edwards Lifesciences averaged −2.4% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.2% | 1 of 5 |
| Next 10 trading days | −3.7% | 1 of 5 |
| Next 15 trading days | −3.0% | 1 of 5 |
| Next 20 trading days | −2.4% | 2 of 5 |
| Next 30 trading days | −4.2% | 2 of 5 |
For scale, EW’s typical 20-trading-day move in either direction is about 5%.
Edwards Lifesciences market cap and key statistics
Edwards Lifesciences’s market cap is $50.82B, with a P/E ratio of 52.5 and revenue of $6.51B over the last twelve months.
Valuation
- Market cap
- $50.82B
- P/E ratio
- 52.5
- Forward P/E
- 26.4
- EPS, TTM
- $1.68
- Gekko Fair Value
- $80.75
Trading
- Volume
- 4.20M
- Avg volume, 20 days
- 3.07M
- 52-week high
- $96.29
- 52-week low
- $72.30
- Shares outstanding
- 576.4M
Financials
- Revenue, TTM
- $6.51B
- Profit margin
- 15.4%
- Return on equity
- 9.2%
- Quarterly earnings growth, YoY
- −25.4%
Risk and income
- Beta
- 0.85
- Typical daily move
- ±2.7%
- Typical 20-day move
- ±5%
Edwards Lifesciences stock news this week
Coverage of Edwards Lifesciences this week reads positive: 4 positive, 3 neutral and 1 negative headlines.
- Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity AheadMarketBeat, Sep 17
- Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit TranscriptSeeking Alpha, Sep 16
- Bank of America Corp DE Takes $605.40 Million Position in Edwards Lifesciences Corporation $EWMarketBeat, Sep 16
- EW DCF Analysis: Intrinsic Value $53 vs Price $86GuruFocus, Sep 16
- Stock Traders Purchase Large Volume of Edwards Lifesciences Call Options (NYSE:EW)MarketBeat, Sep 14
- Edwards Lifesciences Insider Daniel Lippis Sells 619 Shares at $87.51 Following Option ExerciseKalkine Media, Sep 14
Edwards Lifesciences peers
Edwards Lifesciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 17.1% above |
| ABTAbbott Laboratories | Accumulation | 15.5% below |
| DHRDanaher | Neutral | 1.1% above |
| ISRGIntuitive Surgical | Neutral | 12.3% above |
| MDTMedtronic | Neutral | 24.7% below |
| SYKStryker | Buying | 17.1% below |
A peer links to its own page where one exists.
Edwards Lifesciences stock FAQ
What is Edwards Lifesciences’s market cap?
Edwards Lifesciences’s market cap is $50.82B at the Sep 18, 2026 close of $88.26, with 576.4M shares outstanding. The shares trade on a P/E ratio of 52.5.
What is the Edwards Lifesciences stock forecast?
The consensus analyst 12-month price target for Edwards Lifesciences is $100.96, +14.4% from the last close. Of the 17 firms that rated the stock in the last 90 days, 14 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Edwards Lifesciences stock overvalued or undervalued?
On Gekko’s estimate Edwards Lifesciences is overvalued: the Sep 18, 2026 close of $88.26 is 9.3% above Gekko Fair Value of $80.75. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Edwards Lifesciences report earnings next?
Edwards Lifesciences is expected to report on Oct 29, 2026, after the market closes (39 days away). Analysts expect earnings of $0.73 per share on revenue of $1.68B. Edwards Lifesciences beat the earnings estimate in 7 of its last 8 reports, moving 3.5% on average across the report.
What is Edwards Lifesciences’s 52-week high and low?
Edwards Lifesciences’s 52-week high is $96.29 and its 52-week low is $72.30; it closed at $88.26 on Sep 18, 2026, +17.4% over the past year.
Is Edwards Lifesciences stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 5 items with data read as supportive (earnings risk), 2 as mixed (trend and gekkoindex) and 2 as headwinds (fair value and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Edwards Lifesciences the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.